New York Blood Center, Inc.

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Cincinna

As FDA’s biologics center closes in on a decade since responsibility for therapeutic biologics was transferred to CDER, CBER posted a solid, if undramatic, year for approvals in 2012, with six origina

As FDA’s biologics center closes in on a decade since responsibility for therapeutic biologics was transferred to CDER, CBER posted a solid, if undramatic, year for approvals in 2012, with six origina

The Food & Drug Administration is putting its best foot forward heading into the Prescription Drug User Fee Act reauthorization in 2012. The agency finished the year with 30 new molecular entity appro